• Home>
  • Stocks>
  • Glenmark Pharmaceuticals Ltd Share Price
Glenmark Pharmaceuticals Ltd share price logo

Glenmark Pharmaceuticals Ltd Share Price

(GLENMARK)

Mid Cap

Healthcare Sector

₹1541.05▲1.39%

as on 04:01PM, 28 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Option Chain

Glenmark Pharmaceuticals Ltd Performance

  • Day's Low

    Day's High

    ₹1,502.65
    Day's Price Range
    ₹1,546.4

  • 52 Week's Low

    52 Week's High

    ₹936
    52-Week Price Range
    ₹1,830.95
1 Month Return+ 18.84 %
3 Month Return-4.4 %
1 Year Return+ 58.57 %
Previous Close₹1,519.85
Open₹1,525.75
Volume7.86L
Upper Circuit₹1,671.80
Lower Circuit₹1,367.90
Market Cap₹42,888.37Cr

Glenmark Pharmaceuticals Ltd Fundamentals

P/E Ratio

-243.96

PEG Ratio

-12.85

Market Cap

₹42,888.37 Cr

P/B Ratio

1.18

EPS

-50.8

Dividend Yield

0.26

Sector

Pharmaceuticals

ROE

6.98

Glenmark Pharmaceuticals Ltd Analyst Rating

based on 13 analysts

BUY

61.54%

Buy

30.77%

Hold

7.69%

Sell

Based on 13 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1688.15

Source: S&P Global Market Intelligence

Glenmark Pharmaceuticals Ltd Share analysis

Glenmark Pharmaceuticals Ltd price forecast by 13 analysts

Upside of11.07%

High

₹2032

Target

₹1688.15

Low

₹1265

Glenmark Pharmaceuticals Ltd target price ₹1688.15, a slight upside of 11.07% compared to current price of ₹1541.05. According to 13 analysts rating.

Source: S&P Global Market Intelligence

Key events for Glenmark Pharmaceuticals Ltd

  • Glenmark Subsidiary to Cease Manufacturing in Switzerland - 29 Mar, 2025

    Glenmark Pharmaceuticals' subsidiary, IGI Inc., will stop manufacturing in Switzerland by July 31, 2025, to enhance its pipeline by outsourcing to CDMOs. This closure is not expected to impact the company's financials negatively.

  • HSBC Upgrades Glenmark to 'Buy' with 22% Upside - 28 Mar, 2025

    HSBC has upgraded Glenmark Pharmaceuticals to a 'Buy' rating, raising the target price to ₹1,785, citing potential from ISB 2001 and margin expansion. The company is in advanced talks for out-licensing ISB 2001, which could significantly boost sales. Glenmark's core business is also expected to benefit from reduced R&D costs and new product launches, positioning it for a potential re-rating.

  • Glenmark Pharmaceuticals Gains Nifty Inclusion and Licensing Deal - 26 Mar, 2025

    Glenmark Pharmaceuticals has entered a licensing agreement for the oncology drug KN035 and will be added to the Nifty Midcap 150 index. Shares saw fluctuations, reaching an intraday high of Rs 1,489.75.

  • Glenmark Receives FDA Approval for Allergy Eye Drops - 20 Mar, 2025

    Glenmark Pharmaceuticals has received FDA approval for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, an OTC allergy eye drop. This product is bioequivalent to Pataday® and will enhance Glenmark's OTC ophthalmic portfolio in the U.S., addressing market needs and reinforcing its commitment to quality healthcare solutions.

  • Glenmark Launches Empagliflozin for Diabetes Management - 12 Mar, 2025

    Glenmark Pharmaceuticals has launched Empagliflozin and its fixed-dose combinations in India under the Glempa brand, targeting Type 2 Diabetes and cardiovascular risks. The launch aims to provide affordable treatment options for millions of patients, reinforcing Glenmark's commitment to cardiometabolic care.

  • Glenmark Launches OTC Laxative in US Market - 10 Mar, 2025

    Glenmark Pharmaceuticals has launched Polyethylene Glycol 3350, an over-the-counter laxative in the US, targeting the lucrative MiraLAX market, which has annual sales of approximately $555.7 million.

  • Glenmark Pharmaceuticals Rises for Third Straight Session - 05 Mar, 2025

    Glenmark Pharmaceuticals Ltd surged 3.49% to Rs 1380.8, marking its third consecutive day of gains. The stock has increased 49.05% over the past year, despite a 7.94% drop in the last month. The Nifty Pharma index has also declined by 9.06% in the same period.

  • Glenmark Recalls ADHD Medication in US Market - 02 Mar, 2025

    Glenmark Pharmaceuticals is recalling approximately 15 lakh bottles of Atomoxetine Capsules in the US due to CGMP deviations and N-Nitroso Atomoxetine impurity exceeding FDA limits. The recall is classified as Class II, indicating potential temporary health risks.

  • Glenmark Pharmaceuticals Faces Quality Control Issues - 01 Mar, 2025

    The Central Drugs Standard Control Organisation has flagged select batches of 145 drugs, including Glenmark's hypertension medication Telma AM, as not of standard quality for January 2025.

  • Glenmark Launches Epinephrine Injection in US Market - 27 Feb, 2025

    Glenmark Pharmaceuticals has launched its Epinephrine Injection USP, a product eligible for 180 days of CGT exclusivity. Despite this launch, shares fell 1% on the same day.

Insights on Glenmark Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, GLENMARK stock has moved up by 18.8%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 11.41% to 12.12% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 23.05% to 23.51% in Dec 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 46.65% of holdings in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 70.5% return, outperforming this stock by 11.9%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 3.47K Cr → 3.41K Cr (in ₹), with an average decrease of 1.6% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 17.06% to 15.96% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 354.21 Cr → 347.96 Cr (in ₹), with an average decrease of 1.8% per quarter

Glenmark Pharmaceuticals Ltd Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹2,460.29Cr (-)₹3,016.01Cr (↑22.59%)₹3,223.30Cr (↑6.87%)₹3,400.50Cr (↑5.50%)₹3,301.90Cr (↓2.90%)
Net Income-₹330.82Cr (-)-₹1,214.27Cr (↑267.05%)₹340.24Cr (↓128.02%)₹354.49Cr (↑4.19%)₹348.03Cr (↓1.82%)
Net Profit Margin-13.45% (-)-40.26% (↑199.33%)10.56% (↓126.23%)10.42% (↓1.33%)10.54% (↑1.15%)
Value in ₹ crore
Details2021202220232024
Total Assets₹20,882.95Cr (-)₹23,128.70Cr (↑10.75%)₹24,799.42Cr (↑7.22%)₹27,724.16Cr (↑11.79%)
Total Liabilities₹6,073.44Cr (-)₹6,390.11Cr (↑5.21%)₹6,921.95Cr (↑8.32%)₹4,753.54Cr (↓31.33%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹1,579.12Cr (-)₹1,243.42Cr (↓21.26%)₹1,216.07Cr (↓2.20%)₹1,474.06Cr (↑21.22%)-₹495.45Cr (↓133.61%)

Glenmark Pharmaceuticals Ltd Index Inclusions

S&P BSE Momentum

₹1,964.80

-0.8 (▲-15.83%)

S&P BSE 150 MidCap

₹14,418.50

-0.56 (▲-81.33%)

BSE Healthcare

₹41,421.50

-0.12 (▲-48.19%)

Nifty Midcap 100

₹51,672.25

-0.32 (▲-167.15%)

Nifty Midcap 150

₹19,120.35

-0.29 (▲-55.05%)

Nifty 500

₹21,339.55

-0.32 (▲-68.4%)

Nifty LargeMidcap 250

₹14,821.10

-0.33 (▲-48.35%)

Nifty Alpha 50

₹46,004.55

-0.67 (▲-308%)

Nifty MidSmallcap 400

₹17,677.95

-0.2 (▲-36.15%)

Nifty Healthcare

₹13,681.30

-0.47 (▲-64.15%)

BSE 500

₹33,579.22

-0.39 (▲-132.39%)

Nifty 200

₹12,982.75

-0.36 (▲-46.45%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

NIFTY PHARMA

₹21,137.45

-0.65 (▲-137.7%)

S&P BSE 250 LargeMidCap

₹10,029.73

-0.39 (▲-38.93%)

S&P BSE 400 MidSmallCap

₹10,772.07

-0.52 (▲-56.71%)

BSE Mid-Cap

₹41,531.12

-0.68 (▲-285.91%)

Glenmark Pharmaceuticals Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
46.65%
0.00
Foreign Institutions
23.51%
1.99
Mutual Funds
12.12%
6.20
Retail Investors
15.96%
-6.43
Others
1.77%
-3.72

Glenmark Pharmaceuticals Ltd Key Indicators

Details20202021202220232024
Book Value Per Share (₹)215.14250.37322.03335.75278.11
Details20202021202220232024
Earning Per Share (₹)27.534.3835.2113.37-50.8
Details20202021202220232024
Return On Equity %10.7611.7710.429.126.98
Details20202021202220232024
Return On Assets %4.044.654.071.2-5.42

Glenmark Pharmaceuticals Ltd Valuation

Glenmark Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (-275.05x)

December 28, 2023

Today (-243.96x)

March 27, 2025

Industry (53.19x)

March 27, 2025

Highest (95.94x)

September 14, 2023

LowHigh

Glenmark Pharmaceuticals Ltd Earnings and Dividends

  • Glenmark Pharmaceuticals Ltd Earnings Results

    Glenmark Pharmaceuticals Ltd’s net profit jumped 199.03% since last year same period to ₹347.96Cr in the Q3 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated -1.76% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Glenmark Pharmaceuticals Ltd Dividends May,2024

    In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.16%.

    Read More about Dividends

Glenmark Pharmaceuticals Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Glenmark Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.

More on Technical Analysis

Glenmark Pharmaceuticals Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
BUY₹42,888.37 Cr135.28%0.52-₹1,434 Cr₹11,813 Cr
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
BUY₹28,261.80 Cr212.67%0.52₹300 Cr₹1,051 Cr
Jubilant Pharmova Ltd
Jubilant Pharmova Ltd
BUY₹14,156.99 Cr67.4%0.57₹72 Cr₹6,702 Cr
Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd
NA₹4,891.51 Cr14.16%0.79-₹388 Cr₹75 Cr
Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Ltd
BUY₹13,998.90 Cr41.24%0.68₹218 Cr₹1,296 Cr
See all

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is an Indian pharmaceuticals company listed on the National Stock Exchange and Bombay Stock Exchange. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API’s) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements. Glenmark has taken several steps towards achieving a healthy presence in the global markets. In addition to its product portfolio, Glenmark’s aggressive acquisition strategy and product launch activities have helped expand its market reach. The company has been awarded numerous accolades over the years, including consecutive years of being ranked amongst the top 1000 world pharmaceutical companies. It continues to be a frontrunner in providing quality and affordable healthcare solutions in India and abroad.

Revenue: ₹3,301.90Cr as on December 2024 (Q4 24)
Net Profit: ₹348.03Cr as on December 2024 (Q4 24)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Pharmaceuticals Ltd
HeadquartersMumbai
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Glenmark Pharmaceuticals Ltd

What is Glenmark Pharmaceuticals Ltd price today?

Glenmark Pharmaceuticals Ltd share price today stands at ₹1541.05, Open: ₹1525.75, Previous Close: ₹1519.85, High: ₹1546.4, Low: ₹1502.65, 52 Week High: ₹1830.95, 52 Week Low: ₹936.

How to Buy Glenmark Pharmaceuticals Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Glenmark Pharmaceuticals Ltd shares

What are today's traded volumes of Glenmark Pharmaceuticals Ltd?

Today's traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 7.86L.

What is today's market capitalisation of Glenmark Pharmaceuticals Ltd?

Today's market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹42888.37Cr.

What is the 52 Week High and Low Range of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd (GLENMARK)
Price
52 Week High
₹1830.95
52 Week Low
₹936

How much percentage Glenmark Pharmaceuticals Ltd is down from its 52 Week High?

Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1541.05. It is down -15.83% from its 52 Week High price of ₹1830.95

How much percentage Glenmark Pharmaceuticals Ltd is up from its 52 Week low?

Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1541.05. It is up 64.64% from its 52 Week Low price of ₹936